Triple combination therapy against PI3KCDK4/6ER prevented and/or delayed the onset of resistance in treatment-naive ER+/HER2- breast cancer models.

These data support the clinical investigation of p110α-selective inhibitors of PI3K, such as alpelisib, in patients with ER+/HER2- breast cancer who have progressed on CDK4/6ER-based…[Read more]